All In Biotech

Drug Trial Radar · NCT00097669

VITATOPS: A Study of VITAmins TO Prevent Stroke

VITATOPS - A Study of VITAmins TO Prevent Stroke

Last checked: Nov 20, 2026Latest source record: Sep 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 8,164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,164

Actual

Start

Nov 1998

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
VITATOPSGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
National Health and Medical Research Council, Australia; National Heart Foundation, Australia; Medical Health Research Infrastructure Council, Australia
First posted
Nov 25, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The VITATOPS study is a multi-center, randomized, double blind, placebo-controlled secondary stroke prevention trial to determine whether the addition of vitamin supplements (B12 500 ug, B6 25 mg, Folate 2 mg) to best medical/surgical management (including modification of risk factors) will reduce the combined incidence of recurrent vascular events (stroke, myocardial infarction) and vascular death in patients with recent stroke or transient ischemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within seven months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blind fashion to receive multi-vitamins or placebo, 1 tablet daily. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause", whichever occurs first. Our target is to recruit a total of 8,000 patients over the next two years with a median follow-up of 2.5 years. Recruitment to the trial began in November 1998 and is planned to continue until December 2005. We aim to complete final follow-up by the end of 2006. However, the Steering Committee will be flexible in dictating the need for ongoing recruitment and continuing follow-up, depending on the overall rate of the primary outcome event in the entire cohort at each interim analysis.

Conditions

  • Stroke
  • Transient Ischemic Attack

Interventions

  • Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placeboDrug

    multivitamin

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-fatal Stroke, Non-fatal Myocardial Infarction or Death Due to Vascular CausesTime frame: The primary outcome was measured over a median follow-up period of 3.4 years (interquartile range IQR 1.0-5.5 years).

Locations

111 sites in 20 countries. Site status is shown where the registry gives one.

  • JFK Hospital / Seton Hall University

    New York, New York

  • Abington Memorial Hospital

    Abington, Pennsylvania

  • South Carolina VA Hospital

    Columbia, South Carolina

  • University of South Carolina

    Columbia, South Carolina

  • Central Coast Neuroscience Research

    Gosford, Australia

  • Bankstown Hospital

    New South Wales, Australia

  • John Hunter Hospital

    New South Wales, Australia

  • Liverpool Hospital

    New South Wales, Australia

  • Royal Perth Hospital

    Perth, Australia

  • Greenslopes Hospital

    Queensland, Australia

  • Nambour Hospital

    Queensland, Australia

  • Flinders & Griffiths

    South Australia, Australia

  • Royal Hobart Hospital

    Tasmania, Australia

  • Alfred Hospital

    Victoria, Australia

  • Beleura & Frankston Hospital

    Victoria, Australia

  • Box Hill Hospital

    Victoria, Australia

  • National Stroke Research Institute - Austin Health

    Victoria, Australia

  • Fremantle Hospital

    Western Australia, Australia

  • Joondalup Hospital

    Western Australia, Australia

  • Sir Charles Gairdner Hospital

    Western Australia, Australia

  • Karl-Franzens University Graz

    Graz, Austria

  • Algemeen Ziekenhuis Sint-Jan Autonome Verzorgingsinstelling

    Bruges, Belgium

  • Universidade Federal Fluminense & Universidade Federal do Rio de Janeiro

    Rio de Janeiro, Brazil

  • Sarajishvili Institute of Neurology and Neurosurgery

    Tbilisi, Georgia

  • Queen Mary Hospital

    Pokfulam, Hong Kong

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Rajah Muthaiah Medical College

    Annāmalainagar, India

  • St John's Medical College Hospital

    Bangalore, India

  • SP Medical College

    Bikaner, India

  • Baby Memorial Hospital

    Calicut, India

  • KS Hospital

    Chennai, India

  • Care Hopstial

    Hyderabad, India

  • Mahaveer Hospital & Research Centre

    Hyderabad, India

  • Mediciti Hospital

    Hyderabad, India

  • MGM Medical College & MY Hospital

    Indore, India

  • Monilek Hospital

    Jaipur, India

  • Amrita Institute of Medical Science

    Kochi, India

  • Centauri, The Albert Road Clinic

    Kolkata, India

  • CSMMU

    Lucknow, India

  • Christian Medical College & Hospital

    Ludhiana, India

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.